Watch Azenta Inc for free: we tell you when fair value or trend changes.

Azenta Inc (AZTA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Azenta Inc stock $16.94, price $39.16, that is 56.7% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

10 models, one by oneBear $12.71 to bull $22.33 Growth analysisrevenue history, year by year Quality 59/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

Some data Nov 8, 2026

Azenta Inc

AZTA · US

Solid, but very expensive

Our calculation puts a fair price 57% below what the stock costs today.

Low debt

Generates free cash flow

Upbeat coverage

Profit last quarter +88% vs. a year ago.

Quality 59/100

Mixed Growth (revenue 5y +8.9 %/yr in USD)

Loss only from goodwill write-downs · -20.0% net margin (TTM) · excl. goodwill write-downs +4.3%

Insiders bought $163,800 (6M)

Some data

Fair value $16.94 · Strongly overvalued

Trails peers (5/13)

Narrow moat 14/100 · thin data

Watch Azenta Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $16.02 – $124.04 · fair‑value band $12.71 – $22.33 · the $39.16 price screens above the $16.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 5 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow Azenta in your weekly email

Every Wednesday you see whether Azenta is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.

Show moreShow less

It operates through Sample Management Solutions and Multiomics segments.

The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services.

This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services.

The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021.

Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Stock analysis

Azenta Inc (AZTA) currently trades at $39.16, while our model-based Fair Value estimate is $16.94, 57% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Multiples group reads highest at a median of $17.52 per share, and 0 of the 10 models we run sit above the $39.16 price.

Bear case: the Asset-Based group reads lowest at $8.58, and 10 of the 10 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $12.71 (bear) to $22.33 (bull), the price of $39.16 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Azenta Inc reported revenue of $594M in FY2025 versus $514M in FY2021, a compound +3.7%/yr. Reported net income was −$55.8M in FY2025.

Key figures

Market cap $1.8B Small · P/S ratio 2.61 · EPS (TTM) $−2.47 · Net margin −20.0% · Return on equity −7.0% · Return on assets (EBIT) −1.1% (5-year average) · Operating margin −2.3% · Revenue (TTM) $614M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 144% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −57%, AZTA screens richer than that median.

Fair Value models

Bear $12.71 Fair Value $16.94 Bull $22.33

Price $39.16 · Downside -56.7%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

FCF DCF $12.62 $15.67 $19.56 82

Growth DCF $12.60 $15.20 $18.28 80

5Y EBITDA Exit $14.43 $20.20 $26.96 76

All 10 models by family

DCF Models

FCF DCF $12.62 $15.67 $19.56 82

5Y Revenue Exit $12.71 $16.94 $22.33 74

5Y EBITDA Exit $14.43 $20.20 $26.96 76

10Y Revenue Exit $12.39 $15.86 $20.52 68

10Y EBITDA Exit $13.50 $17.79 $23.56 69

Multiples

EV/EBITDA $15.82 $19.81 $23.80 67

EV/Revenue $11.81 $15.22 $18.63 54

Asset-Based

NCAV (Graham) $5.66 $8.58 $10.72 54

Growth DCF

Growth DCF $12.60 $15.20 $18.28 80

Rev-Margin DCF $12.71 $16.96 $21.96 74

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10

How much profit the company makes from its sales and capital

Quality Growth 53

Are margins and returns getting better?

Cashflow 39

Do the profits arrive as real cash?

Financial strength 86

Debt, balance sheet and risk of trouble

Investment 93

Does it invest with discipline instead of growing at any price?

Low Volatility 11

How calm the share price moves, does not count

Price momentum 76

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 76

Distance to the 52-week high, does not count

New shares 97

Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $163,800, on May 18, 2026.

BuyWilliam L CornogDirector10,000 shares at $16.38$163,800May 18, 2026
Plan buyEphraim StarrSVP, Gen Counsel & Secretary335 shares at $24.17$8,097Jul 31, 2026

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+3.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+2.2%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+8.9%

Start year 2020 (pandemic). Over 10 years: +0.7% a year

Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+10.9%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−7.1% (2020) → −1.9% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+29.9%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+3.5%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +26.9% a year for the price and +1.1% for the forecasts.

Forecast 2026 (sales)+3.8%

Forecast 2027 (sales)+3.8%

Projected 2028 (sales)+3.5%

Projected 2029 (sales)+3.3%

Projected 2030 (sales)+3.1%

AZTA screens overvalued: fair value 57% below the price. Compare with Intuitive Surgical, Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype

Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Azenta Stock Outlook After DNA Technology Deal Yahoo Finance · Nov 1, 2026
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities Yahoo Finance · Oct 30, 2026
Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Conference Call and Webcast Yahoo Finance · Oct 28, 2026
Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know Yahoo Finance · Oct 19, 2026

Compare Azenta Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 5/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 59 · Above median

Fair Value upside −56.7% · Bottom 25%

Profitability

Return on assets −2.7% · Bottom 25%

Net margin (12 months) −20.0% · Bottom 25%

Operating margin (12 months) −2.3% · Bottom 25%

Growth and dividend

Revenue growth (quarter YoY) 12.0% · Above median

Balance sheet

Debt / equity 0.03× · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 1.03× · Cheapest 25%

P/S (12 months) 2.89× · Pricier than median

Price / free cash flow (fiscal year) 46.3× · Priciest 25%

EV/EBITDA 46.8× · Priciest 25%

PEG 0.53× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 25

FUTURE (revenue growth)60 · sector 40

PAST (return on equity)0 · sector 30

HEALTH (low debt)99 · sector 96

DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Solventum Corporation SOLV	$90.38	$131.27	+45%	vs AZTA
EssilorLuxottica Société anonyme EL	€193.80	€196.22	+1%	vs AZTA
Intuitive Surgical, Inc ISRG	$452.80	$353.90	−22%	vs AZTA
Medline Inc MDLN	$39.64	$28.59	−28%	vs AZTA
Alcon Inc ALC	CHF 61.30	CHF 34.06	−44%	vs AZTA
Becton, Dickinson and Company BDX	$211.88	$97.80	−54%	vs AZTA
Straumann Holding STMN	CHF 104.50	CHF 45.50	−56%	vs AZTA
West Pharmaceutical Services, Inc WST	$399.81	$139.22	−65%	vs AZTA
Sartorius Stedim Biotech S.A DIM	€225.80	€54.82	−76%	vs AZTA
Sartorius Aktiengesellschaft SRT	€227.00	€42.50	−81%	vs AZTA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Azenta Inc: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/AZTA?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/AZTA.US.svg" width="360" height="84" alt="Azenta Inc: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "Azenta Inc Fair Value". https://www.fairvalue-calculator.com/stock/AZTA

Frequently asked questions

Is Azenta Inc (AZTA) overvalued or undervalued?

As of Nov 8, 2026, our model estimates a fair value of $16.94 versus a price of $39.16, about 57% lower (overvalued).

What is the fair value of AZTA?

Our model-based fair value for Azenta Inc is $16.94 (as of Nov 8, 2026), built from audited fundamentals. The current price: $39.16.

What is the quality score of AZTA?

Azenta Inc has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Azenta Inc (AZTA)?

Our model-based price target is the fair value of $16.94 (as of Nov 8, 2026) from 10 valuation models. Cautious scenario $12.71, optimistic scenario $22.33. It is a calculation from audited fundamentals, not an analyst target.

What is the Azenta Inc stock forecast for 2026?

Our models put fair value at $16.94, about 57% lower versus a price of $39.16 (overvalued). Cautious scenario $12.71, optimistic scenario $22.33. The calculation is refreshed regularly with new filings.

What is the revenue of Azenta Inc (AZTA)?

Azenta Inc reported trailing-twelve-month revenue of about $614M (latest available figure, as of Nov 8, 2026).

What growth is priced into Azenta Inc (AZTA)?

For today's price to be fair in a discounted-cash-flow model, Azenta Inc would have to grow free cash flow by +29.9 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.9 % per year. As of Nov 8, 2026.

What discount rate (WACC) does the fair value of AZTA use?

Our models discount Azenta Inc at 12.7 %: a base by market capitalisation (small), damped by beta 1.52, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Azenta Inc that is +29.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.7 %) and the same formula as our fair value.

How much growth has Azenta Inc (AZTA) delivered so far?

Over the past 5 years revenue at Azenta Inc grew +8.9 % a year. The price currently implies free-cash-flow growth of +29.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Azenta Inc (AZTA) growing?

The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Azenta Inc (+29.9 % per year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Azenta Inc (AZTA)?

The free-cash-flow yield on the price is 2.16 %: that much free cash flow Azenta Inc produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Azenta Inc (AZTA)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Azenta Inc it is $16.94 per share (as of Nov 8, 2026), against a price of $39.16. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).

Is Azenta Inc stock overvalued or undervalued in 2026?

As of Nov 8, 2026, AZTA trades above its calculated fair value: price $39.16, fair value $16.94, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of AZTA?

No. The price is what the market pays today ($39.16); the fair value is what the company's own numbers justify ($16.94). For Azenta Inc the two are $22.22 per share apart. That gap is exactly why we show both numbers side by side.

How much is Azenta Inc worth?

The market values Azenta Inc at about $1.8B (market capitalisation, as of Nov 8, 2026). Per share that is $39.16; our models calculate a fair value of $16.94 per share.

What do the bullish and bearish scenarios say about AZTA?

Our models span a range for Azenta Inc: cautious scenario $12.71, base $16.94, optimistic $22.33 per share (as of Nov 8, 2026, price $39.16). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of AZTA?

The PEG ratio of Azenta Inc is 0.53 (P/E divided by earnings growth, as of Nov 8, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of Azenta Inc (AZTA)?

Balance-sheet figures for Azenta Inc (as of Nov 8, 2026): return on equity −7.0%, debt of 0.03 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.

How far is AZTA from its 52-week high?

Azenta Inc trades at $39.16, about 8% below its 52-week high of $42.73 and 144% above the low of $16.02 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $16.94 is for.

Which stocks are comparable to Azenta Inc?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Azenta Inc stock attractive at the current price?

The data as of Nov 8, 2026: price $39.16, calculated fair value $16.94 (−57%), Quality Score 59/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of AZTA calculated?

We run Azenta Inc through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $16.94 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.3% above its aggregate fair value. Azenta Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Azenta Inc (AZTA)?

The closing price on Nov 6, 2026 was $39.16. Our model-based fair value is $16.94, about 57% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Azenta Inc right now?

The price sits above even our optimistic bull case ($22.33). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Azenta Inc

How large is the market capitalisation of Azenta Inc (AZTA)?

The market capitalisation of Azenta Inc is $1.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Azenta Inc (AZTA)?

The price-to-sales ratio of Azenta Inc is 2.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Azenta Inc (AZTA)?

Earnings per share at Azenta Inc are $−2.47. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Azenta Inc (AZTA)?

The net margin of Azenta Inc is −20.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Azenta Inc (AZTA)?

The return on equity (ROE) of Azenta Inc is −7.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Azenta Inc (AZTA)?

On an EBIT basis the return on assets of Azenta Inc is −1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Azenta Inc (AZTA)?

The operating margin of Azenta Inc is −2.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Azenta Inc (AZTA)?

Revenue at Azenta Inc is growing +12.0% versus a year earlier (3y avg +2.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Azenta Inc (AZTA)?

Earnings per share at Azenta Inc are growing +87.8% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Azenta Inc (AZTA) hold?

Azenta Inc holds more cash than debt, $169M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Azenta Inc in the live analysis

One click puts Azenta Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.